Krsnaa Diagnostics share price jumps 11%: Stock in focus after company enters PET-CT segment
17 Sept, 10:43 IST · Plays out over months · 1 source
Krsnaa Diagnostics won a 15-year Punjab deal to run costly PET-CT cancer scans, so its shares jumped 11% on years of expected scan income, while rival lab chains gain nothing directly.
Key facts
What the reporting establishes, before any reading of it.
- Krsnaa Diagnostics (NSE: KRSNAA) entered PET-CT diagnostic services via a 15-year PPP agreement with the Punjab government.
- Shares surged over 11% on the news (Mint, 17 Sep 2026); the stock had been volatile recently.
- Expansion diversifies revenue beyond pathology/radiology tenders and is expected to provide long-term cash visibility.
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- Krsnaa Diagnostics won a 15-year Punjab government deal to run PET-CT cancer-imaging scans, opening a costly high-value scan business it did not have before.
- The stock jumped 11% as investors priced in years of steady scan income from the long contract.
Who may gain
- Krsnaa Diagnostics gains a 15-year revenue stream and a new high-value PET-CT line; no listed peer shares the award.
Along the supply chain
Downstream
Punjab government hospitals and patients get advanced cancer imaging locally instead of referring cases out.
Upstream
PET-CT scanners come from unlisted global makers (Siemens, GE, Philips) and tracer supply has no listed pure-play, so no listed upstream impact.
Where demand moves
Business
Punjab's public hospitals will send PET-CT scan demand to Krsnaa's new centres for 15 years; scanner makers and tracer suppliers are unlisted so no listed upstream benefit.
Capital
Money rotates into KRSNAA shares on the repricing; no sector-wide rotation since the award is exclusive to one company.
How it spreads across sectors
Healthcare
Mild positive: validates the PPP route for high-end diagnostics and hints other states may tender similar PET-CT deals.
When it plays out
Immediate
Shares already up 11%; follow-through depends on disclosed order value and rollout plan.
Medium term
Scan volumes and revenue/margin contribution from PET-CT over 1-6 months and beyond.
Short term
Agreement signing, centre commissioning schedule, and management commentary in quarterly results.